Mateusz Opyrchal, MD
Hematology & Oncology · Indianapolis, INNPI 1316141658
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (37.4%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Pfizer at 38.9% of the total. 2025 is the largest year on record at $1,982, more than ten times the $115 reported in 2019.
Across 50 payments — averaging $101.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- Regeneron$2K
- AstraZeneca$398
- Merck$175
- Gilead$162
- Tempus AI, Inc$143
- plus $500 from 15 others
Across 161 payments — averaging $6298.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$484K
- AstraZeneca$121K
- Pfizer$105K
- Incyte Corporation$103K
- Bayer$67K
- Eli Lilly$58K
- plus $76K from 2 others
What the payments were for
- Speaking & faculty fees$1,89037%
- Grants$3507%
- Travel & lodging$1,70434%
- Food & beverage$1,10422%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 5 | $1,967 |
| Regeneron | 7 | $1,714 |
| AstraZeneca | 3 | $398 |
| Merck | 5 | $175 |
| Gilead | 7 | $162 |
| Tempus AI, Inc | 2 | $143 |
| Daiichi Sankyo Inc. | 4 | $81 |
| Novartis | 2 | $59 |
| Array Biopharma Inc | 1 | $50 |
| Lilly USA, LLC | 2 | $40 |
| EMD Serono, Inc. | 1 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| GSK | 2 | $29 |
| Menarini Silicon Biosystems, Inc. | 1 | $26 |
| Pharmacosmos Therapeutics Inc. | 1 | $25 |
| Genentech, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Incyte Corporation | 1 | $22 |
| Karyopharm Therapeutics Inc. | 1 | $19 |
| Puma Biotechnology, Inc. | 1 | $18 |
| Sobi, Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IBRANCE$1,890
How this compares
$5,060 in reported general payments places this provider in the 55th percentile of 224 hematology & oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 12 | $168,570 |
| Letrozole | 228 | $6,195 |
| Tamoxifen Citrate | 42 | $1,667 |
| Anastrozole | 86 | $1,042 |
| Dexamethasone | 20 | $119 |
| Trazodone Hcl | 11 | $24 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance | $1,967 | $168,57012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 224 hematology & oncology providers in Indiana.
Other hematology & oncology in Indianapolis
- Richard GaynorIndianapolis$3.7M
- Ruemu BirhirayIndianapolis$3.1M
- Anand TandraIndianapolis$280K
- Attaya SuvannasankhaIndianapolis$253K
- Michael DuganIndianapolis$236K
- Daniel MiltonIndianapolis$231K
- Amro ElshouryIndianapolis$212K
- Brian MulherinIndianapolis$175K
- Muhammad Sarfraz NawazIndianapolis$172K
- John EdwardsIndianapolis$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.